[1]王红英,方靖淞.健脾化瘀通腑方治疗恶性淋巴瘤化疗后肠梗阻脾虚肠燥证疗效研究[J].陕西中医,2024,(11):1512-1516.[doi:DOI:10.3969/j.issn.1000-7369.2024.11.015]
　WANG Hongying,FANG Jingsong.Study on curative effect of Jianpi Huayu Tongfu decoction in treatment of spleen deficiency and intestinal dryness obstruction after chemotherapy for malignant lymphoma[J].,2024,(11):1512-1516.[doi:DOI:10.3969/j.issn.1000-7369.2024.11.015]
点击复制

健脾化瘀通腑方治疗恶性淋巴瘤化疗后肠梗阻脾虚肠燥证疗效研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年11期
页码:
1512-1516
栏目:
临床研究
出版日期:
2024-11-05

文章信息/Info

Title:
Study on curative effect of Jianpi Huayu Tongfu decoction in treatment of spleen deficiency and intestinal dryness obstruction after chemotherapy for malignant lymphoma
作者:
王红英; 方靖淞
(眉山市人民医院,四川 眉山 620010)
Author(s):
WANG Hongying; FANG Jingsong
(Meishan People's Hospital,Meishan 620010,China)
关键词:
恶性淋巴瘤;  肠梗阻;  脾虚肠燥证;  健脾化瘀通腑方;  免疫功能;  肠黏膜屏障
Keywords:
Malignant lymphoma;  Intestinal obstruction;  Spleen deficiency and intestinal dryness;  Jianpi Huayu Tongfu decoction;  Immune function;  Intestinal mucosal barrier
分类号:
R 733
DOI:
DOI:10.3969/j.issn.1000-7369.2024.11.015
文献标志码:
A
摘要:
目的:观察健脾化瘀通腑方治疗恶性淋巴瘤化疗后肠梗阻脾虚肠燥证临床效果。方法:105例恶性淋巴瘤化疗后肠梗阻脾虚肠燥证患者随机分为西医组53例、联合组52例。比较两组临床症状改善情况及脾虚肠燥证的中医证候积分变化、胃肠引流量,治疗前、治疗7 d后两组血清相关因子[二胺氧化酶(DAO)、D-乳酸(D-LC)]和免疫功能[T淋巴细胞亚群(CD4+、CD8+、CD4+/CD8+)、补体(C3、C4)]水平。结果:联合组腹痛、腹胀缓解时间、首次排气及排便时间均短于西医组(P<0.05)。第1～7天,两组胃肠引流量呈下降趋势,且第3～6天联合组低于西医组(P<0.05)。治疗7 d后,两组纳差、倦怠乏力、面色萎黄评分及总积分、血清DAO、D-LC、CD8+较治疗前降低,且联合组治疗后上述指标低于西医组(均P<0.05)。两组T淋巴细胞亚群(CD4+、CD4+/CD8+)、补体C3、C4较治疗前升高,且联合组治疗后高于西医组(均P<0.05)。结论:健脾化瘀通腑方能有效改善恶性淋巴瘤化疗后肠梗阻脾虚肠燥证的临床症状,提升免疫功能,修复损伤的肠黏膜屏障。
Abstract:
Objective:To observe clinical effects of Jianpi Huayu Tongfu decoction in treatment of patients with spleen deficiency and intestinal dryness obstruction after chemotherapy for malignant lymphoma.Methods:105 patients with intestinal obstruction with spleen deficiency and intestinal dryness after malignant lymphoma chemotherapy were randomly divided into western medicine group 53 cases and combined group 52 cases.The improvement status of clinical symptoms and TCM primary syndromes scores of spleen deficiency and intestinal dryness were compared between the two groups.The gastrointestinal drainage volume of the two groups were recorded,levels of serum-related factors [diamine oxidase(DAO),D-lactate(D-LC)] and immune function [T lymphocyte subsets(CD4+,CD8+,CD4+/CD8+),complements(C3,C4)] of the two groups were compared before and after 7 d of treatment.Results:The abdominal pain relief time,abdominal distension relief time,first exhaust time and defecation time in the combined group were all shorter than those in the western medicine group(P<0.05).From first day to seventh day,the gastrointestinal drainage volume in the two groups showed downward trend,and the volume in the combined group from third day to sixth day was less than that in the western medicine group(P<0.05).After 7 d of treatment,the scores of Nacha,Juandai Fali,Mianse Weihuang,total score and levels of serum DAO,D-LC and CD8+ in the two groups were significantly reduced compared with those before treatment.After treatment,the scores and levels were lower in the combined group than those in the western medicine group(all P<0.05).The T lymphocyte subsets(CD4+,CD4+/CD8+)and complements C3 and C4 were significantly enhanced in the two groups compared to before treatment,and the levels in the combined group after treatment were higher than those in the western medicine group(all P<0.05).Conclusion:Jianpi Huayu Tongfu decoction can effectively improve clinical symptoms,enhance body's immune function,repair damaged intestinal mucosal barrier of patients with intestinal obstruction of spleen deficiency and intestinal dryness after chemotherapy for malignant lymphoma.

参考文献/References:

[1] 晏黎,黄伟,饶亚华,等.血清Flt3L和Gas6对非霍奇金淋巴瘤患者化疗后感染的诊断价值[J].中华检验医学杂志,2021,44(10):937-942.
[2] 丁孟德,冯丹丹.大承气汤加减对腹部手术术后早期炎症性肠梗阻患者胃肠功能恢复及预后的影响[J].辽宁中医杂志,2023,50(3):85-88.
[3] 中华人民共和国国家卫生健康委员会.淋巴瘤诊疗规范[J].肿瘤综合治疗电子杂志,2019,5(4):50-71.
[4] 于世英,王杰军,王金万,等.晚期癌症患者合并肠梗阻治疗的专家共识[J].中华肿瘤杂志,2007,19(8):637-640.
[5] 中华中医药学会.中医肿瘤科临床诊疗指南[M].北京:人民卫生出版社,2019:6-10.
[6] 国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:87-90.
[7] 陈佳芸,张子敬,黄展明,等.谢晓华基于“调水道,行津液”针药结合治疗单纯性肠梗阻的思路探讨[J].广州中医药大学学报,2022,39(9):2161-2166.
[8] 陈硕,苏轶男,王凯,等.中药保留灌肠联合针刺治疗在结直肠癌术后的临床运用[J].天津中医药,2022,39(6):746-749.
[9] 金嘉悦,任似梦,韩宝瑾,等.基于药物法象理论探讨恶性淋巴瘤的中医治疗[J].长春中医药大学学报,2023,39(5):484-487.
[10] 惠逸帆,倪海雯,程海波.基于癌毒病机理论辨治恶性淋巴瘤探析[J].中国中医药信息杂志,2023,30(3):142-145.
[11] 徐徐,陈恬,张敏,等.白细胞和血小板计数对淋巴瘤患者外周血造血干细胞采集时机选择的影响[J].陕西医学杂志,2023,52(6):723-727.
[12] 周恒,张博,王小哲,等.利妥昔单抗联合CHOP方案化疗对恶性淋巴瘤患儿的治疗效果[J].癌症进展,2023,21(14):1547-1550,1613.
[13] 杨伟宁,姚锐,王文升.大黄素对术后肠梗阻大鼠胃肠动力,炎症和氧化应激反应的影响及机制研究[J].陕西医学杂志,2023,52(3):252-256.
[14] 张弛,廖良功,胡齐欣.半夏泻心汤保留灌肠治疗转移性结肠癌并发不完全性肠梗阻的临床观察[J].时珍国医国药,2023,34(7):1673-1675.
[15] 王清园,杨巍,彭云花,等.实炎方保留灌肠联合坐浴在Ⅲ度内痔患者选择性痔上黏膜切除钉合术后的应用[J].陕西中医,2022,43(10):1419-1426.
[16] 刘鸿雁,王敏,古玉兰.柴芩承气汤保留灌肠治疗腑实热结型急性胰腺炎疗效及对患者中医症候积分、血清淀粉酶的影响[J].陕西中医,2022,43(11):1551-1555.
[17] 夏清,克晓燕,胡凯文.从脾虚痰浊论治非霍奇金淋巴瘤[J].广州中医药大学学报,2022,39(12):2949-2953.
[18] 钱嘉惠,周春宇,杨成城,等.麻子仁丸治疗术后肠梗阻的网络药理研究[J].世界中医药,2022,17(7):935-940.
[19] 龙莹,张子敬,黄展明,等.电针肺经原络穴治疗大肠癌术后肠梗阻的临床观察[J].广州中医药大学学报,2021,38(3):518-523.
[20] 蒋琴,蒋文军,刘文英,等.急性肠梗阻患儿血清乳酸脱氢酶、碱性磷酸酶、白细胞与高敏C反应蛋白的表达及临床意义[J].实用医学杂志,2021,37(11):1433-1436.
[21] 邵金华,郑金玲,王垂杰,等.健脾化瘀方对慢性萎缩性胃炎小鼠胃黏膜细胞凋亡和NF-κB/Bcl-2通路的影响[J].现代免疫学,2022,42(4):279-291.
[22] 郑月平,苏庆民.瓜蒌“法象”新解[J].中华中医药杂志,2021,36(3):1580-1582.
[23] 高飞,钟辉云,陈可禧,等.大黄有效组分“大黄酸-大黄素”联合治疗溃疡性结肠炎作用机制研究[J].中国中药杂志,2022,47(15):4148-4155.
[24] SUGIMOTO K,UEJIMA S,UCHIYAMA Y,et al.Metachronous primary cancer of the tongue and malignant lymphoma of the small intestine:A case report[J].Medicine(Baltimore),2021,100(7):e24806.
[25] 李哲,玄静,赵振华,等.半夏化学成分及其药理活性研究进展[J].辽宁中医药大学学报,2021,23(11):154-158.
[26] 柳威,邓林华,赵英强.白术及其有效成分药理作用概述[J].中医药学报,2021,49(10):116-118.
[27] 程玥,丁泽贤,张越,等.茯苓多糖及其衍生物的化学结构与药理作用研究进展[J].中国中药杂志,2020,45(18):4332-4340.
[28] 钟民勇,庹福临,乔日发,等.枳壳理气质量标志物的有效性验证[J].中药新药与临床药理,2022,33(3):281-286.

相似文献/References:

[1]李 森,李去病,李 毅.巴林平胶囊联合化疗治疗恶性淋巴瘤临床研究[J].陕西中医,2024,(7):913.[doi:DOI:10.3969/j.issn.1000-7369.2024.07.011]
　LI Sen,LI Qubing,LI Yi.Clinical research on Balinping capsule combined with chemotherapy in treatment of malignant lymphoma[J].,2024,(11):913.[doi:DOI:10.3969/j.issn.1000-7369.2024.07.011]

备注/Memo

备注/Memo:
基金项目:四川省科技厅重点研发项目(2020YFS0399)
更新日期/Last Update: 2024-11-11